Eton Pharmaceuticals vs Protalix BioTherapeutics
ETON and PLX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ETON and PLX compare
Eton Pharmaceuticals is the larger company, worth 7.5 times as much as Protalix BioTherapeutics ($1.8B against $244M).
On earnings, Protalix BioTherapeutics is cheaper: it trades at 13.2× trailing earnings, against 164× for Eton Pharmaceuticals.
Eton Pharmaceuticals grew revenue faster over the last twelve months (81.5% versus 30.1% for Protalix BioTherapeutics).
Protalix BioTherapeutics keeps more of each dollar of sales as profit, with a net margin of 23.5% compared with 12.0% at Eton Pharmaceuticals.
Protalix BioTherapeutics scores higher on the StockData Score (16 against 10 for Eton Pharmaceuticals), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ETON | PLX |
|---|---|---|
| Size and price | ||
| Market cap | $1.8B | $244M |
| Share price | $63.88 | $3.03 |
| Change, 1 year | 278% | 57.0% |
| Change, 5 years | 1414% | 206% |
| Beta (5Y) | −0.44 | 1.33 |
| Employees | 44 | 226 |
| StockData Score | ||
| Total score | 10 | 16 (better) |
| Valuation score | 0 | 4 (better) |
| Growth score | 3 (better) | 2 |
| Performance score | 4 | 4 |
| Health score | 3 | 6 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | 164× | 13.2× (better) |
| P/S | 17.3× | 3.0× (better) |
| P/B | 39.2× | 3.4× (better) |
| EV/EBITDA | 87.6× | 9.3× (better) |
| P/FCF | 124× | 31.8× (better) |
| FCF yield | 0.81% | 3.1% (better) |
| Fair value | $10.29 | $5.40 |
| Margin of safety | −521% | 43.9% (better) |
| Growth | ||
| Revenue growth (TTM) | 81.5% (better) | 30.1% |
| Revenue growth, 5Y average | 360% (better) | −3.5% |
| Net income growth (TTM) | – | 202% |
| EPS growth (TTM) | – | 475% |
| Profitability | ||
| Gross margin | 57.9% | 69.2% (better) |
| Operating margin | 15.4% | 28.9% (better) |
| Net margin | 12.0% | 23.5% (better) |
| FCF margin | 14.0% (better) | 9.5% |
| Return on equity | 36.0% (better) | 31.2% |
| Return on invested capital | 42.5% | 49.5% (better) |
| Financial health | ||
| Debt / equity | 0.60 (better) | 0.00 |
| Net debt / EBITDA | 0.05 | – |
| Interest coverage | 3.6× | – |
| Current ratio | 1.52 | 2.94 (better) |
| Altman Z-score | 16.25 (better) | 5.85 |
| Piotroski F-score | 4 | 4 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 74.0% | 17.9% |
| Held by insiders | 5.6% | 3.8% |
| Insider net buying, 12 months | −$35.0M | $101K (better) |
| Short interest, % of float | 7.4% | 4.5% |
Go deeper
- ETON stock overview
- ETON income statement
- ETON valuation and score
- PLX stock overview
- PLX income statement
- PLX valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.